Abstracts tagged "Lung"

Abstract Number: 2378 • 2013 ACR/ARHP Annual Meeting
Safety Of Mavrilimumab In Cynomolgus Monkeys: Relevance Of Nonclinical Findings In Lung To Human Safety
Patricia C. Ryan¹, Matthew A. Sleeman², Marlon Rebelatto¹, Bing Wang³, Hong Lu⁴, Chi-Yuan Wu³, Dee Wilkins¹, Susan Spitz¹, Gopi Ranganna⁵, Alex Godwood⁶, Alex Michaels⁷, Didier Saurigny⁶, Lorin Roskos⁸, David Close⁶, Heidi Towers⁹, Kathleen McKeever¹ and Rakesh Dixit⁷, ¹Translational Sciences, MedImmune, Gaithersburg, MD, ²Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, ³Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, ⁴Translational Sciences, MedImmune, Hayward, CA, ⁵Clinical Development, MedImmune, LLC, Cambridge, United Kingdom, ⁶MedImmune, Ltd, Cambridge, United Kingdom, ⁷MedImmune, Gaithersburg, MD, ⁸One MedImmune Way, Medimmune, Gaithersburg, MD, ⁹MedImmune, LLC, Cambridge, United Kingdom
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. Mavrilimumab (CAM-3001)…
Abstract Number: 1745 • 2013 ACR/ARHP Annual Meeting
Prediction Of Pulmonary Complications In Systemic Sclerosis – Model Development and Validation
Svetlana I. Nihtyanova¹, Benjamin E. Schreiber², Voon H. Ong³, John G. Coghlan⁴, Athol U. Wells⁵ and Christopher P. Denton⁶, ¹Department of Rheumatology, Royal Free and University College Medical School, London, United Kingdom, ²Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ³Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ⁴National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, ⁵Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁶Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom
Background/Purpose: Pulmonary complications contribute substantially to systemic sclerosis (SSc) associated morbidity and are the most frequent disease-related cause of death. We explore predictors of clinically…
Abstract Number: 2175 • 2012 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Sjogren Syndrome: A Population-Based Study
Carlotta Nannini¹, Adlene Jebakumar², Jay H. Ryu³, Cynthia S. Crowson⁴ and Eric L. Matteson², ¹Rheumatology Unit, Prato Hospital, Prato, Italy, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The reported frequency of pulmonary involvement in primary Sjögren’s Syndrome (pSS) varies widely ranging from 8 to 75% depending on the detection method employed…
Abstract Number: 1713 • 2012 ACR/ARHP Annual Meeting
Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains
Lesley Ann Saketkoo¹, Dörte Huscher², Dinesh Khanna³, Paul F. Dellaripa⁴, Kevin Flaherty⁵, Chester V. Oddis⁶, Kristine Phillips⁷, Athol U. Wells⁸, Christopher P. Denton⁹, Oliver Distler¹⁰, Otylia M. Kowal-Bielecka¹¹, Romy Christmann¹², Nora Sandorfi¹³, David Pittrow¹⁴, Vibeke Strand¹⁵, James R. Seibold¹⁶, Kevin K. Brown¹⁷ and Eric L. Matteson¹⁸, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Department of Critical Care and Pulmonary Medicine, University of Michigan, Ann Arbor, MI, ⁶Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology, University of Michigan, Ann Arbor, MI, ⁸Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ¹⁰Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹¹Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, ¹²Rheumatology, Boston University School of Medicine, Boston, MA, ¹³Division of Rheumatology, Thomas Jefferson Univ Med Coll, Philadelphia, PA, ¹⁴Institute of Clinical Pharmacology - University of Dresden, Dresden, Germany, ¹⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ¹⁶Scleroderma Research Consultants LLC, Avon, CT, ¹⁷Autoimmune Lung Center, National Jewish Hospital, Denver, CO, ¹⁸Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Lack of reliable and valid measures of disease activity and clinical response in patients with connective tissue disease (CTD)-related interstitial lung disease (ILD) makes…
Abstract Number: 1691 • 2012 ACR/ARHP Annual Meeting
Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs
Gudrun Reynisdottir¹, Reza Karimi², Jimmy Ytterberg³, Vijay Joshua¹, Helga Olsen², Aase Haj Hensvold¹, Anders Harju⁴, Johan Grunewald², Sven Nyren⁵, Anders Eklund², Lars Klareskog⁶, Roman Zubarev⁷, Magnus Skold² and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁵Radiology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The aims of the current study was to investigate if inflammatory lung changes are present in RA patients early in the disease process and…
Abstract Number: 1673 • 2012 ACR/ARHP Annual Meeting
Clinical Phenotypes of Caucasian Adult and Juvenile Dermatomyositis Patients with Anti-MDA5 Autoantibodies
Zoe Betteridge¹, Sarah Tansley¹, Harsha Gunawardena², Lucy R. Wedderburn³, Hector Chinoy⁴, Robert G. Cooper⁵, Jiri Vencovsky⁶, Lenka Plestilova⁷, Ingrid E. Lundberg⁸, Katalin Danko⁹, Melinda Vincze¹⁰, Neil McHugh¹¹, UK JDRG¹² and EuMyoNet¹³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom, ³Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁴Rheumatic Diseases Centre, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatic Diseaes Center, Salford Royal Foundation Trust, Salford, United Kingdom, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague 2, Czech Republic, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹University of Debrecen, University of Debrecen, Debrecan, Hungary, ¹⁰University of Debrecen, University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Institute of Child Health, London, United Kingdom, ¹³Rheumatology Unit, Stockholm, Sweden
Background/Purpose: Autoantibodies to MDA5 have been previously reported in Japanese patients with dermatomyositis (DM) and are associated with clinically-amyopathic DM and rapidly progressing interstitial lung…
Abstract Number: 1468 • 2012 ACR/ARHP Annual Meeting
Patient Perspective Informs Core Sets, Constructs of Metrics and Communication Tools for Patients with Connective Tissue Disease Related Interstitial Lung Disease
Shikha Mittoo¹, Sid Frankel², Daphne LeSage³, Flavia V. Castelino⁴, Lisa Christopher-Stine⁵, Sonye Danoff⁶, Aryeh Fischer⁷, Laura K. Hummers⁸, Ami A. Shah⁸, Jeffery J. Swigris⁹, Sophia Cenac¹⁰, Sancia Ferguson¹¹, Ignacio Garcia-Valladares¹², Maithy Tran¹³, Harmanjot K. Grewal¹⁴ and Lesley Ann Saketkoo¹⁵, ¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²University of Manitoba, Winnipeg, Canada, ³Center for CCH at State of Louisiana, New Orleans, LA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Medicine and Neurology, Johns Hopkins University, Baltimore, MD, ⁶Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁷Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Autoimmune Lung Center, National Jewish Health, Denver, CO, ¹⁰Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University Health Science Center, New Orleans, LA, ¹¹Tulane University School of Medicine, ¹²Rheumatology, Guadalajara, Guadalajara, Mexico, ¹³Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁴Rheumatology, Lousiana State University Health Sciences Center, New Orleans, LA, ¹⁵LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA
Background/Purpose: Limited information on the patient experience exists in CTD-ILD. Herein supports that the patients' perspective is essential to informing clinical practice and in…
Abstract Number: 850 • 2012 ACR/ARHP Annual Meeting
Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
Masataka Kuwana¹, Tsutomu Takeuchi² and Junichi Kaburaki³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³Dept of Internal Med, Shinakasaka Clinic, Tokyo, MI, Japan
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). However, only a subset of SSc…
Abstract Number: 693 • 2012 ACR/ARHP Annual Meeting
A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy
Niamh P. Quillinan¹, Deirdre McIntosh², Syed Haq² and Christopher P. Denton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Daval International Ltd, Eastbourne, East Sussex, United Kingdom
Background/Purpose: We have performed a study to explore safety and tolerability of hyperimmune caprine serum (AIMSPRO®) prepared under GMP conditions in established diffuse cutaneous systemic…
Abstract Number: 502 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
Elena Becerra¹, Geraldine Cambridge² and Maria J. Leandro², ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Lung involvement is common in patients with Rheumatoid Arthritis (RA), including interstitial lung disease (ILD), pleural disease and small airway disease. There are no…
Abstract Number: 227 • 2012 ACR/ARHP Annual Meeting
Long Term Outcome of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies and Amyopathic Dermatomyositis
Machiko Mizushima¹, Hidehiro Yamada², Yoshioki Yamasaki¹, Masaomi Yamasaki³, Minoru Satoh⁴ and Shoichi Ozaki⁵, ¹Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ²Internal Medicine, St. Marianna University, Kawasaki, Japan, ³Internal Medicine, St Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan, ⁴Medicine, University of Florida, Gainesville, FL, ⁵Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: The aim of this study was to assess the long term clinical course and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM) and…
Abstract Number: 207 • 2012 ACR/ARHP Annual Meeting
Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis Patients with Pulmonary Involvement – the RIM Study
Cynthia S. Crowson¹, Ann M. Reed², Molly Hein³, Abigail B. Green¹, Consuelo Lopez de Padilla⁴, Rohit Aggarwal⁵, Dana P. Ascherman⁶, Marc C. Levesque⁷ and Chester V. Oddis⁸, ¹Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ⁵Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The Rituximab in Myositis (RIM) Study provides a unique resource for biomarker investigation of homogeneously treated refractory adult and juvenile myositis patients. Building on…
Abstract Number: 222 • 2012 ACR/ARHP Annual Meeting
Lung Nodules in Patients with Idiopathic Inflammatory Myopathies
Laura C. Cappelli¹, Andrew L. Mammen², Sonye K. Danoff³, Grant H. Louie⁴, Thomas E. Lloyd⁵ and Lisa Christopher-Stine⁶, ¹Ste 4500, Johns Hopkins University, Baltimore, MD, ²NIAMS, NIH, Bethesda, MD, ³Medicine/Pulmonary, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD, ⁵Neurology, Johns Hopkins, Baltimore, MD, ⁶Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose: The idiopathic inflammatory myopathies are associated with an increased incidence of malignancy, and interstitial lung disease (ILD) has been reported in as many as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].